Boston Scientific Seeks To Limit Embolization Device Adverse Event Focus
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific recommends that only serious, device- and procedure-related adverse events be defined during clinical testing of vascular and neurovascular embolization devices
You may also be interested in...
Neurovascular, Vascular Embolization Devices Shifting To Class II
FDA is adding vascular devices to its proposed recategorization of neurovascular embolization devices from Class III to Class II with special controls
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.